North America Protein Engineering Market Research Report – Segmented By Product, Technology, Protein Type, End-User & Country (The United States, Canada and Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 13115
Pages: 100

North America Protein Engineering Market Size (2024 to 2029)

The North American market size for protein engineering is forecasted to value USD 52.39 billion by 2029 from USD 30.77 billion in 2023, growing at a CAGR of 11.23% from 2024 to 2029.

The use of protein engineering in the food industry is one factor driving the market forward. Amylases, proteases, and lipases are a few food processing enzymes frequently used in the food industry for baking, brewing, dairy products, dietary supplements, and fats and oils. Protein engineering can modify the properties of some key enzymes or proteins used in food processing and increase the functionality of existing enzymes or proteins for industrial applications. For example, in the food industry, proteases are used for flavor, meat tenderization, and milk coagulation. Our protease engineers are putting a lot of effort into creating modified proteases that can operate more efficiently at low temperatures and alkaline pH levels. In addition, lipases remove lipid stains, cheese flavor, and dough stability.

Y-O-Y growth in the usage of protein engineering in medical applications is another promising factor promoting the growth of the protein engineering market in the North American region. Advanced developments in protein engineering resulted in the production of secreted therapeutic proteins, including interferon, insulin, and other molecules, and combinatorial proteins for therapeutics. The primary field of interest in protein engineering is the development of cancer therapeutics. For example, novel antibodies can be generated using advances in protein engineering and recombinant DNA technologies, which can then be used to create anti-cancer medications. Amunix Pharmaceuticals Inc., a biopharmaceutical company focused on the discovery and development of advanced immuno-oncology therapeutics, has an agreement with Merck in the United States and Canada for rights to develop therapeutics against a target using Amunix’s proprietary platform.

The use of protein engineering in nanobiotechnology is developing over time. The most essential are proteins, which act as structural elements during tissue creation and help move and arrange the other components of a tissue. Nanotechnology-based systems primarily focus on the controlled synthesis and assembly of proteins. The combinatorial biological techniques used in protein engineering, such as monoclonal antibodies and bacterial cell surface display, are also used in nanobiotechnology to screen polypeptide sequences that selectively bind to inorganic surfaces.

The market growth is restrained by the lengthy approval process, high maintenance costs, and lack of qualified persons.

This research report on the North American protein engineering market has been segmented and sub-segmented into the following categories.

By Technology

  • Rational Protein Design
  • Directed Evolution
  • Hybrid Approach

By Product

  • Instruments
  • Reagents
  • Software & Services

By End-User

  • Academic Research Institutes

  • CROs
  • Pharma & Biotech Companies

By Protein Type

  • Insulin

  • Monoclonal Antibodies
  • Vaccines
  • Colony Stimulating Factors
  • Coagulation Factors
  • Interferon

By Country

  • The United States
  • Canada
  • Rest of North America

North America had a significant share of the global protein engineering market in 2022, owing to the factors such as an increase in the adoption of protein drugs, rising chronic diseases, and increasing research and development. For example, 11.3% of the population, or 37.3 million Americans, had diabetes in 2019. In addition, nearly 283,000 Americans under the age of 20 are estimated to have been diagnosed with diabetes, approximately 0.35% of that population. This diabetes requires insulin which is made of proteins.

The United States accounted for the largest share of the North American market in 2021. Generate Biomedicines, a start-up developed by Flagship Pioneering, raised $370 million in series B funding in 2021 to build its de novo protein design process. The company wants to use machine learning to assemble therapeutic proteins, such as cytokines, enzymes, and peptides, from the beginning to treat any illness.

The Tierra Protein Platform, an industry-first eCommerce portal that enables customers to receive customized proteins manufactured, verified, and shipped to them, was launched in 2022, according to Tierra Biosciences. The company's online portal accepts up to 10,000 digital protein sequence entries from clients. The input is then analyzed by Tierra's in-house artificial intelligence (AI) system to determine whether the proteins contain parts that are incompatible with the production process.


Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Merck KGaA, Perkinelmer, Inc., Cytiva, Promega Corporation, Takara Bio, Inc., Genscript Biotech Corporation, Codexis, Inc., New England Biolabs, Inc., Creative Biolabs, and Phynexus, Inc. are a few of the notable players in the North American protein engineering market profiled in this report.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample